$GILD

Three firms—Gilead Sciences, AbbVie, and Visa—offer defensive portfolios substantial free cash flow yields and capital returns amid 2026 market uncertainty.

Boxer Capital invests $9.5M in clinical-stage biotech $TNGX, raising stake to 21.09%, as stock surges 427% amid Gilead partnership momentum.

Patent strength, not clinical efficacy, will drive GLP-1 market leadership as clinical outcomes converge. Companies with robust IP portfolios may capture disproportionate market share despite comparable results.

Advanced drug delivery systems market projected to grow from $299.6B (2025) to $487.4B (2030), driven by chronic diseases, nanotechnology breakthroughs, and oncology applications.

Gilead acquires oncology firm Arcellx for $7.8 billion in cash, adding CAR T-cell cancer therapy to its pipeline. Deal expected to close Q4 2024.

Gilead acquires Arcellx for $7.8B to expand CAR-T therapy portfolio, strengthening oncology pipeline and cell therapy capabilities.

Gilead acquires Arcellx for $7.8B to gain CAR-T therapy anito-cel for multiple myeloma, with FDA approval expected by late 2026.